MacroGen gene delivery systems - Oxford BioMedica
Latest Information Update: 29 Aug 2007
At a glance
- Originator Oxford BioMedica
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Nov 1999 Programme available for licensing (http://www.oxfordbiomedica.co.uk)
- 22 Nov 1999 Preclinical development for Solid tumours in United Kingdom (Unknown route)